Social Prescribing to Improve Adherence and Outcomes in Women With Heart Failure
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Oct 3, 2024
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new approach called "social prescribing" to help women with heart failure stick to their medication and improve their quality of life. Heart failure is a serious condition that affects many women, leading to frequent hospital visits and even death. Unfortunately, many women struggle to follow their medication plans, which can worsen their health. The trial aims to see if connecting these women with community resources and support based on their specific social needs—like help with transportation or mental health services—can lead to better medication adherence and overall well-being.
To participate in this trial, women must be 18 years or older, have a documented diagnosis of heart failure, and score two or more points on a specific questionnaire that identifies social challenges. Participants will be randomly assigned to either receive social prescribing support or standard care from their healthcare team. Those in the social prescribing group will work with a link worker who will help them access tailored services to meet their needs. The trial is not yet recruiting but aims to make a significant impact on the health of women with heart failure by addressing the factors that make it difficult for them to manage their condition.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women
- • 18 years of age or older
- • Documented HF of any etiology
- • Valid personal health identifier
- • Two or more points on the weighted SPARK questionnaire
- Exclusion Criteria:
- • Patients not meeting inclusion criteria
- • Do not take HF medications
- • Not residents of the province where they are being followed or who have opted out from their provincial health registry
- • Patients with severe cognitive impairment or other conditions that significantly impact the ability to participate in SP will also be excluded.
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported